Keryx Biopharmaceuticals — Q3 2017 Earnings Presentation
28 slides from Keryx Biopharmaceuticals's earnings presentation, Nov 7, 2017
Slide 1: U.S. FDA approval of Additional Indication for AURYXIA (ferric citrate) Tablets
U.S. FDA approval of Additional Indication for AURYXIA® (ferric citrate) TABLETS Keryx Biopharmaceuticals, Inc 11/7/2017 www.keryx.com Exhibit 99.2
Slide 2: Agenda
Agenda Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Today’s Announcements & Importance of Auryxia® Greg Madison, President & CEO 3Q 2017 Results Scott Holmes, CFO Auryxia’s Broad Label John Neylan, M.D., Chief Medical Officer Commerci
Slide 3: Forward-Looking Statements
Forward-Looking Statements Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia may be forward-looking statements that involve a number of risks and unce
Slide 4: Today's Announcements
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Today’s Announcements Greg Madison Chief Executive Officer
Slide 5: Today's Announcements: Building a leading kidney care company
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Today’s Announcements Building a leading kidney care company
Slide 6: 3Q 2017 Financial Results
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. 3Q 2017 Financial Results Scott Holmes Chief Financial Officer
Slide 7: 3Q 2017 Auryxia Prescription Demand
3Q 2017 Auryxia Prescription Demand Copyright © 2017 by Keryx Biopharmaceuticals, Inc. IMS / Specialty mix 3Q 2017: 55% / 45% * Impacted by overall mix of business between Medicare Part D, Commercial and Government Sources: IMS, Davita Rx, Fresenius Rx and Keryx data on file. Gross-to-net: 56%* +18%
Slide 8: Selected Financial Results
Selected Financial Results Copyright © 2017 by Keryx Biopharmaceuticals, Inc. ($ in millions) Three Months Ended Sept. 30, 2017 (unaudited) Three Months Ended Sept. 30, 2016 (unaudited) Nine Months Ended Sept. 30, 2017 (unaudited) Nine Months Ended Sept. 30, 2016 (unaudited) Net U.S. Auryxia Product
Slide 9: Importance of Auryxia
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Importance of Auryxia® Greg Madison Chief Executive Officer
Slide 10: Auryxia (ferric citrate) Tablets: New Indication
Auryxia® (ferric citrate) Tablets Copyright © 2017 by Keryx Biopharmaceuticals, Inc. New Indication: treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis Broad label supports use of Auryxia as a first-line treatment option Auryxia’s expanded indication now
Slide 11: Overview of Iron Deficiency Anemia in Chronic Kidney Disease
Overview of Iron Deficiency Anemia in Chronic Kidney Disease Copyright © 2017 by Keryx Biopharmaceuticals, Inc. One in seven people in the US has chronic kidney disease (CKD), more than half of them estimated to be iron deficient Occurs when the body does not have enough iron to produce sufficient n
Slide 12: Auryxia's Profile
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Auryxia’s Profile John Neylan, M.D. Chief Medical Officer
Slide 13: High Levels of Hepcidin Impair GI Absorption of Iron
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. High Levels of Hepcidin Impair GI Absorption of Iron Sources: (7) Babitt JL. J Am Soc Nephrol. 2012;23:1631-1634. (8) Goodnough LT, et al. Blood. 2010;116:4754-4761. (13) National Institute of Diabetes and Digestive and Kidney Diseases. https://www.
Slide 14: Auryxia (ferric citrate) Tablets: Broad Label
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. INDICATIONS AND USAGE Auryxia is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis Auryxia is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney di
Slide 15: Statistically Significant, Rapid Improvement in Hemoglobin
Statistically Significant, Rapid Improvement in Hemoglobin Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Phase 3 Design: 16-week randomized, double-blind, placebo-controlled study, followed by an 8-week open-label safety extension phase Ferric citrate or matching placebo initiated at 3 tablets/
Slide 16: Auryxia Safety Profile
Auryxia® Safety Profile Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Source: Fishbane, JASN 2017 Pivotal Phase 3 study: Auryxia was well tolerated Majority of adverse events were mild to moderate Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia Incidence
Slide 17: ASN 2017: Keryx Accepted Abstracts
ASN 2017: Keryx Accepted Abstracts Oral: Ferric Citrate Reduces FGF23 in Patients With Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Iron Deficiency Anemia (IDA) Irrespective of the Change in Serum Phosphate (P) Authors: Block GA, Pergola PE, Uhlig K, Neylan JF, Fishbane S, Chertow GM
Slide 18: Thank You!
THANK YOU! Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Source: Fishbane, JASN 2017 To the… Patients who participated in our clinical trials and their families Physicians Nurses Study coordinators U.S. Food & Drug Administration
Slide 19: Commercial Strategy and Launch Focus
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Commercial Strategy and Launch Focus Doug Jermasek VP, Marketing and Strategy
Slide 20: Promotional Marketing Campaign
Promotional Marketing Campaign Copyright © 2017 by Keryx Biopharmaceuticals, Inc.
Slide 21: Adults in the U.S. with Iron Deficiency Anemia and Chronic Kidney Disease
Adults in the U.S. with Iron Deficiency Anemia and Chronic Kidney Disease Copyright © 2017 by Keryx Biopharmaceuticals, Inc. 30 MILLION U.S. ADULTS WITH CKD ~650K treated for Iron Deficiency Anemia ~350K on phosphate binders ~ 450K on dialysis 250K-400K Market development opportunity ~ 1.7MM adults
Slide 22: Key Launch Objectives
Key Launch Objectives Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Drive rapid awareness of new indication in iron deficiency anemia Differentiate Auryxia from existing treatment options Communicate favorable reimbursement access to Auryxia
Slide 23: New Indication Provides Significant Commercial Leverage
New Indication Provides Significant Commercial Leverage Copyright © 2017 by Keryx Biopharmaceuticals, Inc. 95 Renal Sales Specialists Current Physician Targets Care for 450,000 dialysis patients Care for 1.7 million pre-dialysis CKD patients Auryxia Conversations Auryxia Covered on all major Medicar
Slide 24: Closing Remarks
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Closing Remarks Greg Madison Chief Executive Officer Keryx Biopharmaceuticals, Inc
Slide 25: Key Takeaways
Key Takeaways Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Remainder of 2017 focused on: Educating physicians about Auryxia Field team training Continue to drive adoption in dialysis for Auryxia’s use as a phosphate binder Building foundation to achieve vision of multi-product kidney care comp
Slide 26: Strong Foundation to Build a Leading Kidney Care Company
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Phosphate Management Anemia Management Strong Foundation to Build a Leading Kidney Care Company THANK YOU!
Slide 27: Strong Foundation to Build a Leading Kidney Care Company
Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Phosphate Management Anemia Management Strong Foundation to Build a Leading Kidney Care Company
Slide 28: U.S. FDA approval of Additional Indication for AURYXIA (ferric citrate) Tablets
U.S. FDA approval of Additional Indication for AURYXIA® (ferric citrate) TABLETS Keryx Biopharmaceuticals, Inc 11/7/2017 www.keryx.com
Keryx Biopharmaceuticals — Q3 2017 Earnings Presentation on 6ix